Financial Data and Key Metrics Changes - The third quarter revenue was $12 million, a decline of 6% from the same quarter in fiscal 2023, with expectations of gradual improvement starting from Q3 [5][11] - Gross margin dipped to 35% for the quarter compared to 41% for the same period last year, with expectations for improvement as revenue expands [14][20] - The loss for the third quarter was approximately $2.6 million compared to $2.5 million in the prior year, with an adjusted EBITDA loss of approximately $1.7 million for the quarter [20][21] Business Line Data and Key Metrics Changes - Sales and marketing expense remained unchanged at $1.7 million, while G&A expense was mostly flat at $2 million compared to $1.9 million in Q3 2023 [6] - R&D expense was approximately $2.2 million compared to $3.2 million in the year-ago period, with a significant reduction in investment towards drug discovery efforts [41] Market Data and Key Metrics Changes - The company noted a modest uptick in clinical bookings, although this area has lagged behind internal expectations [12] - There has been a loosening of R&D budgets in the biotech sector, with increased activity observed in recent months compared to the previous year [17][27] Company Strategy and Development Direction - The company is focusing on expanding work with larger pharmaceutical companies, which generally have more stable budgets compared to smaller biotech firms [3][27] - The company is actively engaged in raising capital to support growth and is evaluating potential near-term licensing opportunities [4][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging third quarter but expressed confidence in positive developments that will lead to improving results in the coming quarters [11][28] - The anticipated turnaround has taken longer than expected, but management is optimistic about achieving quarterly profitability and expanding operating margins over time [27][28] Other Important Information - The company ended the quarter with $4.5 million in cash and no debt, with cash used in operating activities approximately $900,000 [21][30] - The total cost of sales increased to $7.8 million compared to $7.5 million in the third quarter last year, primarily due to increased mouse costs [29] Q&A Session Summary Question: What is the progress update on Corellia AI and investment during Q3? - Management indicated a significant reduction in investment for Corellia in Q4 and Q1, while expressing optimism about potential out-licensing deals for some assets [19][33] Question: What are the expectations regarding the press release and customer budgets? - Management acknowledged a technical issue with the press release timing and noted that customer budgets are showing signs of improvement, although it is still early to determine the extent of recovery [43][44]

[Management Commentary and Business Outlook](index=1&type=section&id=Management%20Commentary%20and%20Business%20Outlook) Management acknowledges a challenging economic environment, particularly in the biotech sector, which has impacted revenue growth. In response, the company is strategically reducing costs to improve short-term results. Despite the downturn, leadership remains confident in a future rebound and is actively seeking capital for its AI subsidiary, Corellia, AI, while progressing its lead targets towards potential licensing deals - The company is navigating a challenging economic environment that began approximately one year ago, particularly affecting the biotech sector[3](index=3&type=chunk) - Strategic initiatives include 'right-sizing' the business to reduce costs and improve short-term financial results without impacting long-term potential[3](index=3&type=chunk) - The company is actively engaged in raising capital for its wholly owned AI subsidiary, Corellia, AI[3](index=3&type=chunk) - Two lead drug targets are progressing, with a potential licensing deal anticipated in the coming quarters[3](index=3&type=chunk) [Third Quarter Fiscal 2024 Financial Performance](index=1&type=section&id=Third%20Quarter%20Fiscal%2024%20Financial%20Performance) For the third quarter of fiscal 2024, Champions Oncology reported a 5.9% decrease in revenue to $12.0 million, primarily due to prior-period customer cancellations. Gross margin contracted to 34.7% from 39.7% year-over-year due to lower revenue against fixed costs and operational inefficiencies. The company recorded an operating loss of $2.6 million and an adjusted EBITDA loss of $1.7 million, both slightly wider than the prior year's quarter [Q3 Revenue and Profitability](index=1&type=section&id=Q3%20Revenue%20and%20Profitability) Q3 FY2024 vs Q3 FY2023 Key Financial Metrics | Metric | Q3 FY2024 | Q3 FY2023 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $12.0M | $12.8M | -5.9% | | Gross Margin | 34.7% | 39.7% | -5.0 p.p. | | Loss from Operations | ($2.6M) | ($2.5M) | +4.1% | | Adjusted EBITDA Loss | ($1.7M) | ($1.6M) | +6.3% | - The decline in revenue was primarily attributed to customer cancellations in prior periods, which led to lower study revenue in the current quarter[4](index=4&type=chunk)[5](index=5&type=chunk) - Lower gross margin was a result of decreased revenue against relatively fixed costs, combined with higher variable costs from operational inefficiencies[7](index=7&type=chunk) [Q3 Operating Expenses](index=2&type=section&id=Q3%20Operating%20Expenses) Q3 FY2024 Operating Expenses (in thousands) | Expense Category | Q3 FY2024 | Q3 FY2023 | YoY Change | | :--- | :--- | :--- | :--- | | Cost of Oncology Solutions | $7,849 | $7,699 | +1.9% | | Research & Development | $2,186 | $3,202 | -31.7% | | Sales & Marketing | $1,797 | $1,761 | +2.0% | | General & Administrative | $2,764 | $2,569 | +7.6% | - The significant decrease in R&D expense was primarily due to reduced investment in the company's target discovery program[8](index=8&type=chunk) - The increase in G&A expense was mainly driven by higher compensation, recruiting expenses, and an increase in bad debt reserves[8](index=8&type=chunk) [Q3 Cash Flow](index=2&type=section&id=Q3%20Cash%20Flow) - Net cash used in operating activities was approximately **$920,000** for the quarter, primarily due to the operational loss[9](index=9&type=chunk) - Net cash used in investing activities was approximately **$125,000** for investments in lab and computer equipment[9](index=9&type=chunk) - There were no financing activities during the third quarter of fiscal year 2024[9](index=9&type=chunk) [Year-To-Date Fiscal 2024 Financial Performance](index=2&type=section&id=Year-To-Date%20Fiscal%202024%20Financial%20Performance) For the first nine months of fiscal 2024, revenue decreased by 11.4% to $36.2 million compared to the same period last year. The gross margin fell to 38.7% from 45.6%. This resulted in a significantly wider loss from operations of $7.1 million and an adjusted EBITDA loss of $4.8 million, compared to losses of $2.7 million and $0.4 million, respectively, in the prior year period. The company ended the quarter with $4.5 million in cash and no debt [YTD Revenue and Profitability](index=2&type=section&id=YTD%20Revenue%20and%20Profitability) YTD FY2024 vs YTD FY2023 Key Financial Metrics | Metric | YTD FY2024 | YTD FY2023 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $36.2M | $40.8M | -11.4% | | Gross Margin | 38.7% | 45.6% | -6.9 p.p. | | Loss from Operations | ($7.1M) | ($2.7M) | +163% | | Adjusted EBITDA Loss | ($4.8M) | ($0.4M) | +1100% | - The year-to-date revenue decline was also attributed to customer cancellations in fiscal year 2023, leading to lower study revenue in fiscal 2024[10](index=10&type=chunk) [YTD Operating Expenses](index=3&type=section&id=YTD%20Operating%20Expenses) YTD FY2024 Operating Expenses (in thousands) | Expense Category | YTD FY2024 | YTD FY2023 | YoY Change | | :--- | :--- | :--- | :--- | | Cost of Oncology Solutions | $22,151 | $22,194 | -0.2% | | Research & Development | $7,494 | $8,693 | -13.8% | | Sales & Marketing | $5,288 | $5,153 | +2.6% | | General & Administrative | $8,305 | $7,494 | +10.8% | - The decrease in R&D expense was primarily from reduced investment in the target discovery program[13](index=13&type=chunk) - The increase in G&A expense was mainly due to higher compensation, recruiting expenses, and allowances for bad debt, partially offset by lower IT costs[13](index=13&type=chunk) [YTD Cash Flow and Financial Position](index=3&type=section&id=YTD%20Cash%20Flow%20and%20Financial%20Position) - Net cash used in operating activities for the nine-month period was **$4.3 million**[14](index=14&type=chunk) - Net cash used in investing activities was **$950,000**, primarily for lab and computer equipment[14](index=14&type=chunk) - Net cash used in financing activities was **$382,000**, resulting from stock repurchases offset by proceeds from option exercises[14](index=14&type=chunk) - The company ended the quarter with approximately **$4.5 million** in cash and cash equivalents and **no debt**[15](index=15&type=chunk) [Financial Statements and Reconciliations](index=5&type=section&id=Financial%20Statements%20and%20Reconciliations) The provided financial statements detail the company's performance. The Statement of Operations shows increased net losses for both the third quarter and year-to-date periods. The Balance Sheet indicates a decrease in total assets and a shift to a stockholders' deficit. The Statement of Cash Flows reflects negative cash flow from operations for the nine-month period, a significant reversal from the positive cash flow in the prior year. GAAP to Non-GAAP reconciliations are provided to adjust for stock-based compensation [Consolidated Statements of Operations](index=6&type=section&id=Consolidated%20Statements%20of%20Operations) Q3 FY2024 Statement of Operations Highlights (in thousands) | Line Item | Q3 FY2024 | Q3 FY2023 | | :--- | :--- | :--- | | Oncology Services Revenue | $12,019 | $12,773 | | Loss from Operations | ($2,577) | ($2,458) | | Net Loss | ($2,530) | ($2,439) | | Net Loss per Share (basic & diluted) | ($0.19) | ($0.18) | YTD FY2024 Statement of Operations Highlights (in thousands) | Line Item | YTD FY2024 | YTD FY2023 | | :--- | :--- | :--- | | Oncology Services Revenue | $36,153 | $40,799 | | Loss from Operations | ($7,085) | ($2,735) | | Net Loss | ($7,167) | ($2,774) | | Net Loss per Share (basic & diluted) | ($0.53) | ($0.20) | [Consolidated Balance Sheets](index=7&type=section&id=Consolidated%20Balance%20Sheets) Balance Sheet Highlights (in thousands) | Account | Jan 31, 2024 | Apr 30, 2023 | | :--- | :--- | :--- | | Cash and cash equivalents | $4,468 | $10,118 | | Total current assets | $13,198 | $19,457 | | Total assets | $26,787 | $34,311 | | Total liabilities | $28,845 | $29,675 | | Stockholders' equity (deficit) | ($2,058) | $4,636 | [Consolidated Statements of Cash Flows](index=8&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Nine Months Ended Jan 31 Cash Flow Summary (in thousands) | Cash Flow Activity | 2024 | 2023 | | :--- | :--- | :--- | | Net cash (used in) provided by operating activities | ($4,321) | $4,664 | | Net cash used in investing activities | ($947) | ($2,112) | | Net cash (used in) provided by financing activities | ($382) | $86 | | Net decrease in cash | ($5,650) | $2,638 | | Cash at end of period | $4,468 | $11,645 | [GAAP to Non-GAAP Reconciliation](index=5&type=section&id=GAAP%20to%20Non-GAAP%20Reconciliation) Q3 Net Loss Reconciliation (in thousands) | Metric | Q3 FY2024 | Q3 FY2023 | | :--- | :--- | :--- | | Net Loss - GAAP | ($2,530) | ($2,439) | | Stock-based compensation | $379 | $331 | | Net Loss - Non-GAAP | ($2,151) | ($2,108) | Q3 EPS Reconciliation | Metric | Q3 FY2024 | Q3 FY2023 | | :--- | :--- | :--- | | EPS - GAAP | ($0.19) | ($0.18) | | Effect of stock-based compensation | $0.03 | $0.02 | | EPS - Non-GAAP | ($0.16) | ($0.16) |

Financial Data and Key Metrics Changes - The second quarter revenue was $11.6 million, a decline of 19% from the second quarter of fiscal 2023 [7] - The loss for the second quarter of 2024 was approximately $2 million, compared to a gain of $8,000 in the prior year [7] - Gross margin for the quarter was 43%, down from 49% for the same period last year [8] - Adjusted EBITDA loss was approximately $1.4 million for the quarter, compared to an adjusted EBITDA profit of $686,000 in the year-ago period [26] Business Line Data and Key Metrics Changes - The total cost of sales was $6.6 million, a decline of 9% compared to $7.2 million in the second quarter last year [8] - R&D expense was approximately $2.5 million, slightly down from $2.6 million in the year-ago period, with $1.2 million invested in drug discovery efforts [27] Market Data and Key Metrics Changes - Cancellations have receded back to historical levels, indicating a potential stabilization in the market [4][35] - The company noted a mixed outlook from pharmaceutical and biotech companies regarding budget planning for the upcoming year [16] Company Strategy and Development Direction - The company has made operational changes, including key hires and internal restructuring, to improve efficiencies and operations [4] - There is a focus on expanding the clinical biomarkers pipeline and ex vivo offerings to drive long-term revenue growth [23] - The company anticipates a gradual improvement in operational results, including revenue growth and profitability within the next couple of quarters [11] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about a return to revenue growth and profitability, despite recent revenue weakness [5][11] - The company is confident that bookings, a leading indicator of revenue, remain strong, and operational corrections are beginning to take effect [11][35] - Management acknowledged that while the environment is not as robust as a couple of years ago, it is better than the previous year, with larger pharmaceutical companies showing healthier budgets [16][37] Other Important Information - The company ended the quarter with $5.5 million in cash and no debt, with cash generated from operating activities of approximately $600,000 [28] - The company anticipates remaining in a generally cash-neutral position for the next quarter or two, with gradual acceleration expected towards the end of fiscal 2024 [10] Q&A Session Summary Question: Are cancellations broad-based or due to one or two large cancellations? - Management indicated that cancellations were broad-based and not due to one or two customers, reflecting an industry-wide trend [14] Question: What are the expectations from pharma and biotech companies for next year? - Management noted mixed feelings, with larger pharmaceutical companies showing healthier budgets compared to smaller biotech firms [16][32] Question: How is the company positioned for future growth? - Management expressed confidence in the company's robust bookings and operational improvements, indicating a positive outlook for returning to normal profitability and growth [35][40]

PART I – FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations, changes in equity, and cash flows, along with explanatory notes [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section presents the company's financial position, including assets, liabilities, and equity, as of October 31, 2023, and April 30, 2023 Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Oct 31, 2023 (unaudited) | Apr 30, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $5,513 | $10,118 | | Total current assets | $14,017 | $19,457 | | Total assets | $28,294 | $34,311 | | **Liabilities & Equity** | | | | Total current liabilities | $20,950 | $21,733 | | Total liabilities | $28,201 | $29,675 | | Total stockholders' equity | $93 | $4,636 | | Accumulated deficit | ($81,954) | ($77,317) | [Unaudited Condensed Consolidated Statements of Operations](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) This section details the company's revenues, expenses, and net loss for the three and six months ended October 31, 2023 and 2022 Operating Results for the Three Months Ended October 31 (in thousands, except per share) | Metric | 2023 | 2022 | | :--- | :--- | :--- | | Oncology services revenue | $11,573 | $14,281 | | Total costs and operating expenses | $13,528 | $14,274 | | Income (loss) from operations | ($1,955) | $7 | | Net loss | ($2,071) | ($16) | | Net loss per common share | ($0.15) | $0.00 | Operating Results for the Six Months Ended October 31 (in thousands, except per share) | Metric | 2023 | 2022 | | :--- | :--- | :--- | | Oncology services revenue | $24,134 | $28,026 | | Total costs and operating expenses | $28,641 | $28,303 | | (Loss) Income from operations | ($4,507) | ($277) | | Net loss | ($4,637) | ($335) | | Net loss per common share | ($0.34) | ($0.02) | [Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity) This section outlines the changes in the company's stockholders' equity, including the impact of net loss and share repurchases - Total stockholders' equity decreased from **$4.6 million** at April 30, 2023, to **$93,000** at October 31, 2023. The decrease was primarily driven by a net loss of **$4.6 million** and common stock repurchases totaling approximately **$708,000**, partially offset by stock-based compensation and proceeds from stock option exercises[76](index=76&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section summarizes the company's cash inflows and outflows from operating, investing, and financing activities Cash Flow Summary for the Six Months Ended October 31 (in thousands) | Cash Flow Activity | 2023 | 2022 | | :--- | :--- | :--- | | Net cash (used in) provided by operating activities | ($3,402) | $3,091 | | Net cash used in investing activities | ($821) | ($1,358) | | Net cash (used in) provided by financing activities | ($382) | $86 | | **Net (decrease) increase in cash** | **($4,605)** | **$1,819** | | Cash at end of period | $5,513 | $10,826 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and disclosures supporting the unaudited condensed consolidated financial statements - The company believes its cash on hand of **$5.5 million**, along with expected cash from operations, is adequate to fund operations for at least the next 12 months. However, it acknowledges that if revenue expectations are not met, cost reduction strategies may be implemented[94](index=94&type=chunk) Disaggregated Revenue for Six Months Ended October 31 (in thousands) | Service Line | 2023 | 2022 | | :--- | :--- | :--- | | Pharmacology services | $22,735 | $26,236 | | Other TOS revenue | $1,381 | $1,679 | | Personalized oncology services | $18 | $111 | | **Total oncology services revenue** | **$24,134** | **$28,026** | - The company initiated a share repurchase program on March 29, 2023, authorizing up to **$5.0 million** in purchases. As of October 31, 2023, approximately **120,300 shares** were repurchased for about **$708,000**, leaving **$4.3 million** available[150](index=150&type=chunk) - Royalty expenses related to licensed tumor models were approximately **$126,200** for the six months ended October 31, 2023, compared to **$108,000** for the same period in 2022[32](index=32&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses a significant decline in oncology services revenue, attributing it to an increase in study cancellations, leading to an operating loss and lower margins, while expressing confidence in liquidity [Overview and Recent Developments](index=21&type=section&id=Overview%20and%20Recent%20Developments) This section provides an overview of the company's business, core offerings, and strategic initiatives in drug discovery and development - The company is a technology-enabled research organization focused on drug discovery and development, utilizing pharmacology, biomarker, and data platforms[38](index=38&type=chunk) - Core offerings include Translational Oncology Solutions (TOS) using the TumorGraft Technology Platform, and Lumin Bioinformatics, a Software as a Service (SaaS) program for computational cancer research[39](index=39&type=chunk)[40](index=40&type=chunk) - The company is actively developing its own pipeline of therapeutic targets and regularly evaluates strategic options for its drug discovery business, such as spin-outs or capital raises[42](index=42&type=chunk)[43](index=43&type=chunk) [Liquidity and Capital Resources](index=21&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses the company's cash position, accumulated deficit, and management's assessment of its ability to fund operations - As of October 31, 2023, the company had **$5.5 million** in cash and an accumulated deficit of approximately **$82.0 million**[45](index=45&type=chunk) - For the six months ended October 31, 2023, the company experienced a net loss of **$4.6 million** and used **$3.4 million** in cash from operations[45](index=45&type=chunk) - Management believes current cash and expected cash flows are sufficient to fund operations for at least the next 12 months, with cost reduction strategies available if needed[45](index=45&type=chunk) [Operating Results](index=22&type=section&id=Operating%20Results) This section analyzes the company's revenue, costs, and operating loss, highlighting key drivers of financial performance Comparison of Operating Results for the Six Months Ended October 31 (in thousands) | Metric | 2023 | 2022 | % Change | | :--- | :--- | :--- | :--- | | Oncology services revenue | $24,134 | $28,026 | (13.9)% | | Cost of oncology services | $14,302 | $14,495 | (1.3)% | | Research and development | $5,308 | $5,491 | (3.3)% | | Sales and marketing | $3,491 | $3,392 | 2.9% | | General and administrative | $5,540 | $4,925 | 12.5% | | **(Loss) Income from operations** | **($4,507)** | **($277)** | **1,527.1%** | - The **13.9% decrease** in six-month revenue was attributed to an increase in study cancellations during fiscal year 2023, which reduced net bookings and available convertible revenue[47](index=47&type=chunk) - Gross margin for the six months ended October 31, 2023, decreased to **40.7%** from **48.3%** in the prior year, primarily due to the decline in revenue against a relatively unchanged cost base[49](index=49&type=chunk) [Cash Flows](index=23&type=section&id=Cash%20Flows) This section provides a detailed breakdown of cash flows from operating, investing, and financing activities for the period - Net cash used in operating activities was **$3.4 million** for the six months ended October 31, 2023, primarily due to the net loss for the period[22](index=22&type=chunk) - Net cash used in investing activities was **$821,000** for the six months ended October 31, 2023, for investments in lab and computer equipment[23](index=23&type=chunk) - Net cash used in financing activities was **$382,000** for the six months ended October 31, 2023, reflecting the stock repurchase program, offset by cash from stock option exercises[24](index=24&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=24&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company, as a smaller reporting company, is not required to provide the information for this item - As a smaller reporting company, the company is exempt from providing disclosures about market risk[59](index=59&type=chunk) [Controls and Procedures](index=24&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of October 31, 2023. No material changes to the internal control over financial reporting were identified during the quarter [Evaluation of Disclosure Controls and Procedures](index=24&type=section&id=Evaluation%20of%20Disclosure%20Controls%20and%20Procedures) This section details management's assessment of the effectiveness of the company's disclosure controls and procedures - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level as of October 31, 2023[3](index=3&type=chunk) - The evaluation confirmed that required information is recorded, processed, summarized, and reported within the timeframes specified by the SEC[3](index=3&type=chunk) [Changes in Internal Control Over Financial Reporting](index=24&type=section&id=Changes%20in%20Internal%20Control%20Over%20Financial%20Reporting) This section reports on any material changes to the company's internal control over financial reporting during the quarter - There were no changes in the company's internal control over financial reporting during the quarter that have materially affected, or are reasonably likely to materially affect, these controls[4](index=4&type=chunk) PART II – OTHER INFORMATION [Legal Proceedings](index=25&type=section&id=Item%201.%20Legal%20Proceedings) The company reports that it is not currently party to any legal proceedings - None[7](index=7&type=chunk) [Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors) As a smaller reporting company, this section is not required. The company refers readers to the Risk Factors section in its Annual Report on Form 10-K filed on July 24, 2023 - As a smaller reporting company, this item is not required. The company directs readers to its Form 10-K filed on July 24, 2023, for a discussion of risk factors[8](index=8&type=chunk) [Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities](index=25&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%2C%20Use%20of%20Proceeds%2C%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company reported no unregistered sales of equity securities or use of proceeds from such sales. It provided an update on its ongoing share repurchase program, noting that approximately $708,000 worth of common stock has been purchased under the $5.0 million authorization, leaving a balance of $4.3 million [Unregistered Sales of Equity Securities](index=25&type=section&id=Unregistered%20Sales%20of%20Equity%20Securities) This section reports on any unregistered sales of equity securities by the company - None[9](index=9&type=chunk) [Use of Proceeds](index=25&type=section&id=Use%20of%20Proceeds) This section reports on the use of proceeds from any equity security sales - None[10](index=10&type=chunk) [Issuer Purchases of Equity Securities](index=25&type=section&id=Issuer%20Purchases%20of%20Equity%20Securities) This section provides details on the company's common stock repurchase program and recent purchases - On March 29, 2023, the Board approved a share repurchase program authorizing up to **$5.0 million** of the company's common stock[11](index=11&type=chunk) - As of October 31, 2023, the company had purchased approximately **120,300 shares** at an average price of **$5.73 per share**, for a total of about **$708,000**[11](index=11&type=chunk) - Approximately **$4.3 million** remains available for repurchases under the authorized program[11](index=11&type=chunk) [Defaults Upon Senior Securities](index=25&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - None[12](index=12&type=chunk) [Mine Safety Disclosures](index=25&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[13](index=13&type=chunk) [Other Information](index=25&type=section&id=Item%205.%20Other%20Information) The company reports no other information for this item - None[14](index=14&type=chunk) [Exhibits](index=26&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the report, including CEO and CFO certifications (Sections 302 and 906) and iXBRL data files - The report includes certifications from the Principal Executive Officer and Principal Financial Officer as required by Sections 302 and 906 of the Sarbanes-Oxley Act[16](index=16&type=chunk) - Interactive Data Files (iXBRL documents) are also filed as exhibits[16](index=16&type=chunk)

Champions Oncology, Inc. (NASDAQ:CSBR) Q1 2024 Earnings Conference Call September 13, 2023 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Matt Hewitt - Craig-Hallum David Baron - Baron Capital Operator Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2024 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this ...

revenue recognized during the period. Deferred revenue is classified as a current liability on the condensed consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year. Accounts receivable and unbilled services were as follows (in thousands) Note 4. Revenue from Contracts with Customers | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|--------------|--------------|--------|-------| | | | | | | | | | | | | Three July | Months 31, | Ended | ...

Champions Oncology, Inc. (NASDAQ:CSBR) Q4 2023 Earnings Conference Call July 24, 2023 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Scott Henry - ROTH Capital Operator Greetings, and welcome to Champions Oncology's Fourth Quarter and Fiscal Year-End 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No þ Commission file number 001-11504 CHAM ...

Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2023 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Matthew Hewitt - Craig-Hallum Operator Good day, everyone, and welcome to the Champions Oncology Third Quarter Fiscal Year 2023 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Dr. Ronnie Morris, Chief Executive Officer of Champions Oncology. Sir, the floor is yours. Ronnie ...

Form 10-Q | --- | --- | |----------------------------------------------------------------------------|--------------------------------------------| | (Exact name of registrant as \nDelaware | defined in its charter) \n52-1401755 | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | | | | One University Plaza, Suite 307 | 07601 | | Hackensack, New Jersey | (Zip Code) | (Address of principal executive of ices) Not Applicable (Former name, former address ...